Non Small-Cell Lung Cancer Market - 2022-2031
The Non Small-Cell Lung Cancer Market was valued at USD 25.4 billion in 2022 and is anticipated to reach USD 47.4 billion by 2031, at a CAGR of 0.084 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non Small-Cell Lung Cancer Market.
This report delivers a comprehensive overview of the Non Small-Cell Lung Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Small-Cell Lung Cancer Market. The Non Small-Cell Lung Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.
Non Small-Cell Lung Cancer Market Scope:
By Drug Class
This report delivers a comprehensive overview of the Non Small-Cell Lung Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Small-Cell Lung Cancer Market. The Non Small-Cell Lung Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Non Small-Cell Lung Cancer Market.
This report delivers a comprehensive overview of the Non Small-Cell Lung Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Small-Cell Lung Cancer Market. The Non Small-Cell Lung Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.
Non Small-Cell Lung Cancer Market Scope:
By Drug Class
- Epidermal Growth Factor Receptor (EGFR) Inhibitors
- Anaplastic Lymphoma Kinase (ALK) Inhibitors
- ROS1 Inhibitors
- BRAF Inhibitors
- Others
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Adenocarcinoma
- Others
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Eli Lilly and Company
- Sanofi
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Pfizer Inc.
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
- Astellas
This report delivers a comprehensive overview of the Non Small-Cell Lung Cancer Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Non Small-Cell Lung Cancer Market. The Non Small-Cell Lung Cancer Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2022–2031.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Class
3.2. Snippet by Type
3.3. Snippet by Treatment
3.4. Snippet by End-user
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with non-small-cell lung cancer
4.1.3. Opportunity
4.1.3.1. Increasing research activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. ARTIFICIAL INTELLIGENCE ANALYSIS
9. BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
9.4. ROS1 Inhibitors
9.5. BRAF Inhibitors
9.6. Others
10. BY TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.1.2. Market Attractiveness Index, By Type
10.2. Squamous Cell Carcinoma*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Large Cell Carcinoma
10.4. Adenocarcinoma
10.5. Others
11. BY TREATMENT
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.1.2. Market Attractiveness Index, By Treatment
11.2. Chemotherapy*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Targeted Therapy
11.4. Immunotherapy
12. BY END-USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.2. Market Attractiveness Index, By End-user
12.3. Hospitals*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Homecare
12.5. Specialty Clinics
12.6. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Eli Lilly and Company*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Sanofi
15.3. Novartis AG
15.4. F. Hoffmann-La Roche Ltd
15.5. Merck & Co., Inc.
15.6. Pfizer Inc.
15.7. AstraZeneca
15.8. Boehringer Ingelheim
15.9. Bristol-Myers Squibb Company
15.10. Astellas (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Drug Class
3.2. Snippet by Type
3.3. Snippet by Treatment
3.4. Snippet by End-user
3.5. Snippet by Region
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising FDA Approval for non-small-cell lung cancer treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with non-small-cell lung cancer
4.1.3. Opportunity
4.1.3.1. Increasing research activities
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 ANALYSIS
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. RUSSIA-UKRAINE WAR ANALYSIS
8. ARTIFICIAL INTELLIGENCE ANALYSIS
9. BY DRUG CLASS
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
9.1.2. Market Attractiveness Index, By Drug Class
9.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Anaplastic Lymphoma Kinase (ALK) Inhibitors
9.4. ROS1 Inhibitors
9.5. BRAF Inhibitors
9.6. Others
10. BY TYPE
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
10.1.2. Market Attractiveness Index, By Type
10.2. Squamous Cell Carcinoma*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Large Cell Carcinoma
10.4. Adenocarcinoma
10.5. Others
11. BY TREATMENT
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
11.1.2. Market Attractiveness Index, By Treatment
11.2. Chemotherapy*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Targeted Therapy
11.4. Immunotherapy
12. BY END-USER
12.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.2. Market Attractiveness Index, By End-user
12.3. Hospitals*
12.3.1. Introduction
12.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.4. Homecare
12.5. Specialty Clinics
12.6. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.7.1. U.S.
13.2.7.2. Canada
13.2.7.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.7.1. Germany
13.3.7.2. U.K.
13.3.7.3. France
13.3.7.4. Italy
13.3.7.5. Spain
13.3.7.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.7.1. Brazil
13.4.7.2. Argentina
13.4.7.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.7.1. China
13.5.7.2. India
13.5.7.3. Japan
13.5.7.4. Australia
13.5.7.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Product Benchmarking
14.3. Company Share Analysis
14.4. Key Developments and Strategies
15. COMPANY PROFILES
15.1. Eli Lilly and Company*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. Sanofi
15.3. Novartis AG
15.4. F. Hoffmann-La Roche Ltd
15.5. Merck & Co., Inc.
15.6. Pfizer Inc.
15.7. AstraZeneca
15.8. Boehringer Ingelheim
15.9. Bristol-Myers Squibb Company
15.10. Astellas (*LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
